March 8, 2010 (FinancialWire) — ProUroCare Medical Inc. (OTCBB: PUMD) has named Michael Chambers and James L. Davis to its board of directors.

Chambers is an attorney, angel investor and entrepreneur. He currently serves as president and CEO of Swift biotechnology, a company he recently co-founded. Swift is pursuing development of screening technologies, developed by the Mitchell Cancer Institute, for gynecological cancers.

Prior to Swift, Chambers helped found InnoRx Pharmaceuticals in 1999, a privately held company that specialized in the development of drugs and drug delivery systems for ocular disease. He served as president and CEO of InnoRx until negotiating its sale to SurModics in 2005.

Davis is an active investor in ProUroCare and other entrepreneurial companies throughout the U.S. Davis is president of Davis & Associates, Inc., a company he founded more than 30 years ago that represents lighting and controls manufacturers throughout the upper Midwest.

Minnesota-based ProUroCare Medical Inc. is a provider of proprietary medical imaging products.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.